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OBJECTIVES The aim of this study was to compare the relative cost of a transesophageal echocardiography
(TEE)-guided strategy versus conventional strategy for patients with atrial fibrillation (AF)
2 days duration undergoing electrical cardioversion over an eight-week period.
BACKGROUND The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) trial
found no difference in embolic rates between the two approaches. However, the TEE-guided
strategy had a shorter time to cardioversion and a lower rate of composite bleeding. While similar
clinical efficacy was concluded, the relative cost of these two strategies has not been explored.
METHODS Two economic approaches were employed in the ACUTE trial. The first approach was based
on hospital charge data from complete hospital Universal Billing Code of 1992 forms, a
detailed hospital charge questionnaire, or imputation. Regression analysis was used to
investigate the added cost of adverse events. The second economic approach involved the
development of an independent analytic model simulating treatment and actual ACUTE
outcome costs as a validation of clinically derived data. Sensitivity analysis was performed on
the analytic model to investigate the potential range in cost differences between the strategies.
RESULTS A total of 833 of the 1,222 patients were enrolled from 53 U.S. sites; TEE-guided (n 420) and
conventional (n  413). At eight-week follow-up, total mean costs did not significantly differ
between the two groups, respectively ($6,508 vs. $6,239; difference of $269; p  0.50).
Cumulative costs were 24% higher in the conventional group, primarily due to increased incidence
of bleeding and hospital costs associated with bleeding. A separate analytic model showed that
treatment costs were higher for the TEE-guided strategy, but outcome costs were higher for the
conventional strategy. Sensitivity analysis of the analytic model illustrated that varying the
incidence and cost of major bleeding and the cost of TEE had the greatest impact on cost
differences between the two groups.
CONCLUSIONS In patients with AF2 days duration undergoing electrical cardioversion, the TEE-guided group
showed little difference in patient costs compared with the conventional group. The TEE strategy
had higher initial treatment costs but lower outcome-associated costs. Cumulative costs were 24%
higher in the conventional group, primarily due to bleeding. The TEE-guided strategy is an
economically feasible approach compared with the conventional strategy. (J Am Coll Cardiol
2004;43:1217–24) © 2004 by the American College of Cardiology Foundationw
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gtrial fibrillation (AF) is the most common arrhythmia seen
n clinical practice in the U.S. affecting 2.3 million Amer-
cans (1,2). By 2050, it is projected that over 5.6 million
mericans will have AF with over 50% of subjects being 80
See page 1225
ears or older (2). Atrial fibrillation is important since it
ontributes to the incidence of ischemic stroke, heart failure,
nd mortality. Thus, AF is considered as a new epidemic
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Manuscript received September 25, 2002; revised manuscript received February 28,t003, accepted November 17, 2003.ith significant public health implications (3). However, the
verall economic burden of treating AF is not well known.
Electrical cardioversion is used to restore sinus rhythm,
ut the procedure itself may be associated with an increased
isk of stroke in patients with AF 2 days’ duration (4–6).
ransesophageal echocardiography (TEE) with short-term
nticoagulation has been proposed as an alternative to the
onventional strategy of seven to eight weeks of anticoagu-
ation in this group of patients (7,8).
The Assessment of Cardioversion Using Transesophageal
chocardiography (ACUTE) trial was a randomized study
hat compared the TEE-guided approach to the conven-
ional approach (9,10). There was no difference in compos-
te embolic events between groups; however, the composite
leeding rate was significantly lower in the TEE-guided
roup. An important secondary end point of the study was
he relative cost of the two management strategies over an
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Cost Analysis of Cardioversion in AF April 7, 2004:1217–24ight-week period (9). We now present a detailed prospec-
ive economic analysis of the ACUTE trial.
ETHODS
atient population. Of the 1,222 patients in the ACUTE
rial, 833 (68%) were enrolled in the U.S. and comprised the
tudy population for the economic analysis. Only U.S.
atients were enrolled in the economic substudy of the
CUTE trial due to vastly different healthcare systems and
ssociated costs between countries. The study design and
linical outcomes manuscripts for the ACUTE trial have
een previously published (9,10). Patients were randomly
ssigned to either the TEE-guided strategy or the conven-
ional anticoagulation strategy (Fig. 1). The institutional
eview board approved the study at each participating site,
nd informed consent was obtained from all patients (10).
conomic methodology. Two economic approaches were
mployed in the ACUTE trial (11–14). The first approach
as based on hospital charge data from the date of enroll-
ent through eight-week follow-up. Where possible, treat-
ent and outcome costs were derived for this time period
Abbreviations and Acronyms
ACUTE  Assessment of Cardioversion Using
Transesophageal Echocardiography trial
AF  atrial fibrillation
CPI  Consumer Price Index
ICER  incremental cost-effectiveness ratio
QALY  quality-adjusted life year
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
UB92  Universal Billing Code of 1992
igure 1. A diagram illustrating the Assessment of Cardioversion Using
ransesophageal Echocardiography trial (ACUTE) protocol. Patients were
andomly assigned to either a transesophageal echocardiography (TEE)-
uided or conventional group; TEE-guided patients, without thrombus by
EE, received early cardioversion with short-term therapeutic anticoagu-
ation. Transesophageal echocardiography-guided patients with thrombus
eceived three weeks anticoagulation and repeat TEE. Conventional
atients received no TEE and three weeks anticoagulation before cardio-
ersion. All patients received four weeks of therapeutic anticoagulationpfter cardioversion. DCC  direct current cardioversion.irectly from complete hospital Universal Billing Code of
992 (UB-92) forms for both inpatient and outpatient
isits. In the absence of UB92s, hospitals were asked to
enerate a detailed hospital charge questionnaire indicating
otal charges (including technical and professional compo-
ents) for all patient admissions and visits during the study
eriod. The charges in the questionnaires were based on
ospital bills. For any U.S. patient where neither UB92s nor
ospital charge questionnaires were available, multivariable
inear regression, based on the charge details derived above,
as used to impute missing patient charge information (14).
ecause hospital charges often include a profit margin and
re not equivalent to actual costs, the standard approach of
harge conversion using hospital-specific cost-to-charge
atios was utilized (11,15). Physician costs (19.6% of hos-
ital costs) were added to converted hospital charges to
btain total patient treatment costs (16,17). The Consumer
rice Index (CPI) annual inflation rate was used to adjust all
osts to the year 2000 U.S. dollars. A discount rate of 3%
as also used, where applicable.
The second economic approach was implemented to
alidate the results of the hospital charge method described
bove. It involved the development of an analytic model
imulating treatment and outcome costs for the 833 U.S.
atients in the ACUTE trial. This analysis parallels previ-
us investigation on model costs (12,13). Actual treatment
nd outcome probabilities were derived from the U.S.
atient population (10). The outcome costs included the
ost of an embolic stroke, major and minor bleeding, and
eath. These costs were adjusted to the year 2000 U.S.
ollars using the CPI and discounted at an annual rate of
%. These costs were obtained from the following sources:
) Mean hospital and physician charges derived from the
Cleveland Clinic Foundation cost accounting system
(converted using appropriate cost-to-charge ratios for
costs related to anticoagulation blood tests, direct current
cardioversion, warfarin, and hospitalization, based on
length of stay derived for the ACUTE study;
) Medicare reimbursement (for transthoracic echocardiog-
raphy [TTE] and TEE costs);
) Published sources (for cerebrovascular accident, transient
ischemic attack, bleeding, and death) (12,18).
Sensitivity analysis was performed on the analytic model
o investigate the potential range in cost differences between
he TEE-guided and conventionally treated groups. A
ne-way sensitivity analysis was performed by varying the
ncidence and cost of stroke, major and minor bleeding, and
eath observed in the ACUTE trial. A range of TEE costs
as also investigated, as this was an additional cost incurred
nly to the treatment group and has the potential to affect
he cost effectiveness of the TEE-guided treatment com-
ared with conventional treatment.
tatistical analysis. Differences in mean costs between the
reatment groups (TEE minus conventional) were com-
ared on an intention-to-treat basis (19). For categorical
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April 7, 2004:1217–24 Cost Analysis of Cardioversion in AFariables, analysis included frequencies and percentages. For
ontinuous variables, analysis included the mean and SD.
ecause the data were not normally distributed, the boot-
trap method was used to derive sample means and bias-
orrected confidence levels for 1,000 samples with replace-
ent (19,20). Analysis of variance methods were used to
etermine if costs varied between treatment groups in the
verall population as well as in the subsets of patients who
ad clinical events. Unless otherwise stated, statistical test-
ng was conducted using two-sided alternatives with a type
error of 0.05.
ESULTS
aseline characteristics. Of 833 patients included in the
conomic substudy of the ACUTE trial, 420 patients
elonged to the TEE-guided group and 413 patients to the
onventional group. The baseline clinical characteristics of
hese patients were well matched (Table 1).
Table 1. Baseline Clinical Data for U.S. Patien
Analysis
Variables
Age, yrs
Male gender, n (%)
Inpatients, n (%)
Functional status (DASI score)
Hypertension, n (%)
Congestive heart failure, n (%)
NYHA class III or IV, n (%)
Left ventricular ejection fraction, (%)
Previous cardioversion, n (%)
Previous embolic event, n (%)
Rhythm at enrollment, n (%), AF/atrial flutter
Estimated duration of AF, days median (interquartil
Left atrial area, cm2
Data presented as mean  SD, n (%), or median (interquarti
Patients with AF were randomly assigned to either a transes
AF  atrial fibrillation; DASI  Duke Activity Sta
transesophageal echocardiography.
able 2. Total Mean Hospital- and Physician-Derived Costs of T
atients Over an Eight-Week Pericardioversion Period
Total Derived Costs TEE-Guided Conventional
 833
ean  SD $6,508  4,917 $6,239  6,370
osts from hospital/physician bills
n  369
Mean  SD $7,199  6,155 $6,808  8,660
osts from questionnaires
n  107
Mean  SD $5,158  3,164 $5,455  5,838
osts from linear regression
n  357
Mean  SD $6,089  3,409 $5,960  3,120
ata are presented in U.S. dollars. Also shown are patient subsets indicating cos
uestionnaires (n  107), and patients with costs derived from the linear regression
ifference in mean cost comparisons for total ACUTE population and each patientCI  confidence interval; TEE  transesophageal echocardiography.verall hospital and physician-derived costs. Table 2
hows the total hospital and physician-derived costs be-
ween the TEE-guided and conventional groups for the 833
atients using the charge data derived from UB92s, charge
uestionnaires, and from multivariable linear regression. A
otal of 369 patients (44%) from 20 sites had complete
B-92s; 107 patients (13%) from 10 sites lacked complete
B-92s but had total hospital charges summarized in the
CUTE questionnaire. A total of 357 patients (43%) had
either UB-92s nor completed patient questionnaires, and,
herefore, their cost data were imputed using multivariable
inear regression techniques. The multivariable model can
e found in the Appendix of this paper. The confidence
ntervals associated with the bootstrap sample replication
nd related p values are also indicated in Table 2.
Overall, there was no significant difference in the mean
erived eight-week total costs between the TEE-guided and
onventional groups ($6,508 vs. $6,239; mean difference of
nrolled in the ACUTE Trial on Cost
TEE-Guided
(n  420)
Conventional
(n  413)
67  12 66.6  13
295 (71) 288 (71)
308 (73) 295 (71)
31  13 29  18
245 (60) 246 (61)
120 (29) 129 (32)
61 (20) 58 (20)
49  16 48  16
50 (12) 52 (13)
30 (7) 41 (10)
401 (95)/19 (5) 392 (95)/21 (5)
e) 8 (4–26) 9 (4–25)
24.7  7.3 24.9  7.5
e). No statistically significant difference for all comparisons.
eal echocardiography-guided and/or conventional strategy.
dex; NYHA  New York Heart Association; TEE 
-Guided and Conventional Management Strategies for 833 U.S.
ifference p Value
Bootstrap Results
Mean Cost
Difference 95% CI p Value
$269 0.50 $386 $486 to $985 0.503
$391 0.62 $841 $1,434 to $1,900 0.642
$297 0.73 $868 $2,284 to $1,212 0.666
$129 0.71 $350 $551 to $874 0.678
ved from hospital/physician charges (n  369), patients with costs derived from
357); Bootstrap results of 1,000 samples (bias corrected) with replacement for the
are included.ts E
e rang
le rang
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tus InEE
D
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Cost Analysis of Cardioversion in AF April 7, 2004:1217–24269; p  0.50). Similarly, the bootstrapping results indi-
ated no significant difference between groups (mean dif-
erence of $386; p  0.50). In the overall model, an
xtended length of stay typically contributes significantly to
ncreased hospital costs, but there was no significant differ-
nce in length of stay between the TEE-guided and
onventional groups (p  0.34, Wilcoxin).
atient care costs of adverse events. Table 3 presents the
ean patient costs associated with adverse events between
he TEE-guided and conventional groups in the ACUTE
rial from enrollment to eight-week follow-up. These costs
re based on the converted hospital charge information
reviously described in Table 2. The added costs represent
he incremental costs of adverse events to the overall mean
osts and were derived using multiple regression (Table 3).
he 95% confidence intervals, using regression coefficients
ncluding age, gender, death (both cardiac- and noncardiac-
elated), bleeding (both major and minor), and cerebrovas-
ular accident/transient ischemic attack are also shown.
For each adverse event, there were no significant differ-
nces between the TEE and the conventional groups in
ean patient costs with similar adverse events. Based on the
ncidence of major and minor bleeding and the hospital cost
ssociated with bleeding, the cumulative total hospital cost
as 24% higher for the conventional group compared to the
EE-guided group. Regression analysis showed that major
leeding added $16,285 to the overall mean cost of $6,374
or each patient in both groups as noted in Table 2. Thus,
ttempts to reduce the incidence of bleeding should have a
ositive economic impact as well as clinical benefit to
ffected patients.
nalytic model of treatment and outcome costs. Tables 4
o 6 show total treatment costs per patient in the TEE-
able 3. Mean Costs and Added Costs* for Treatment of Patien
CUTE Clinical Trial
Event
Mean Costs
TEE-Guided Convention
VA (n  4) (n  2)
Mean  SD 17,713  9,035 11,673  2,4
VA/TIA (n  5) (n 3)
Mean  SD 16,003  8,708 10,898  2,2
ajor bleed (n  5) (n  8)
Mean  SD 24,902  9,379 22,004  17,
inor bleed (n  7) (n  20)
Mean  SD 12,057  12,431 12,311  10,
omposite bleed (n  11)† (n  28)
Mean  SD 15,609  11,544 15,080  13,
ardiac death (n  5) (n  2)
Mean  SD 10,259  5,259 11,796  13,
oncardiac death and UNK death (n  4) (n  2)
Mean  SD 18,417  9,572 7,337  3,6
omposite death (n  9) (n  4)
Mean  SD 13,885  8,165 9,566  8,3
ata presented in U.S. dollars. *Added costs report regression coefficients from regress
inor bleed, and CVA/TIA included in the respective equation. These added costs
n both groups. †One patient had both major and minor bleeds.
CI  confidence interval; CVA  cerebrovascular accident; TEE  transesophauided group versus the conventional group using the becond economic approach—the analytic model. This was
sed to validate the results of the ACUTE economic
ubstudy. The overall treatment costs were somewhat lower
han those found in the first economic approach (hospital
harge data), but the resulting trend was similar. The net
ost per patient demonstrated little difference ($79.57)
etween the TEE-guided and the conventional groups.
ensitivity analysis of the analytic model. Sensitivity
nalysis showed that major bleeding (Fig. 2A) and the
ost of the TEE (Fig. 2B) had the greatest impact on
ost differences. Complete sensitivity analysis for the inci-
ence and costs of stroke, death, and minor bleeding can be
ound in the online-only Appendix of this paper at www.
ardiosource.com/jacc.html. Doubling the incidence of ma-
or bleeding in both treatment groups (to 2.4% and 3.9% in
EE-guided and conventional groups, respectively) resulted
n overall savings using the TEE treatment as opposed to
onventional treatment once the cost of a major bleeding
vent was in excess of $20,500 per event (Fig. 2A). Main-
aining event incidence but varying the cost of TEE did not
esult in savings until the cost of the TEE was reduced from
277 to $185 (Fig. 2B). Conversely, increasing the cost of
he TEE from $277 to $1,000 resulted in the TEE-guided
roup costing 17% more than the conventionally treated
roup ($4,166 vs. $3,446). Overall, using sensitivity analysis,
ost differences varied from $896 in savings to $1,610 in
dditional costs for the TEE strategy.
ISCUSSION
he results of the economic analysis of the ACUTE trial
how that in 833 randomized U.S. patients there is little
ifference in total patient costs over an eight-week period
verse Events During the Eight-Week Study Period in the
Added Costs
p Value Incremental Costs 95% CI p Value
0.43 $5,756 $1,526 to $9,986 0.008
0.37 $5,194 $1,549 to $8,840 0.005
0.74 $16,285 $13,364 to $19,206  0.001
0.96 $4,492 $2,485 to $6,499  0.001
0.91 $8,487 $6,720 to $10,253  0.001
0.82 $3,769 $124 to $7,662 0.058
0.21 $2,637 $1,670 to $6,944 0.230
0.40 $5,788 $2,845 to $8,730  0.001
odel with ACUTE patient age, gender, cardiac death, noncardiac death, major bleed,
nt the incremental costs of adverse events to the overall mean costs for each patient
hocardiography; TIA  transient ischemic attack; UNK  unknown.ts’ Ad
al
80
08
396
441
231
309
51
73
ion m
represe
geal ecetween the TEE-guided and the conventional groups.
Table 4. ACUTE Trial Analytic Model of Treatment Costs Using ACUTE Trial Data on 833 Patients
Treatment
TEE-Guided Strategy (n  420)
Total Costs Conv #
Conventional-Guided Strategy (n  413)
Unit Cost TEE # Frequency Frequency Total Costs Reference
TTE $213.68 378 1.0 $80,771.04 370 1.0 $79,061.60 2000 Medicare reimbursement
TEE $277.16 363 1.0 $100,609.08 13 1.0 $3,603.08 2000 Medicare reimbursement
Repeat TEE $277.16 22 1.0 $6,097.52 0 1.0 $0.00 2000 Medicare reimbursement
Hospitalization $486.75 308 5.5 $824,554.50 295 5.7 $818,470.13 CCF cost/charge 2000
aPTT $21.50 210 5.0 $22,575.00 170 5.0 $18,275.00 CCF cost/charge 2000
Warfarin $0.70 420 32.0 $9,408.00 413 56.0 $16,189.60 CCF cost/charge 2000
PT/INR tests $10.40 420 4.6 $20,092.80 413 9.0 $38,656.80 CCF cost/charge 2000
DCC $146.08 305 1.0 $44,554.40 198 1.0 $28,923.84 CCF cost/charge 2000
Gross total $1,108,662.34 Gross total $1,003,180.05
Per patient cost $2,639.67 Per patient cost $2,429.01
aPTT activated partial thromboplastin time; Conv conventional; CCF The Cleveland Clinic Foundation; DCC direct current cardioversion; PT/INR prothrombin time/international normalized ratio; TEE transesophageal
echocardiogram; TTE  transthoracic echocardiography.
Table 5. ACUTE Trial Analytic Model of Outcomes Costs Using ACUTE Trial Results on 833 Patients
Outcome Unit Cost Multiplier Frequency Per Patient Cost Multiplier Frequency Per Patient Cost Reference
CVA $28.212 0.00952 4 $268.58 0.00484 2 $136.55 Seto (12) 2000 discounted
TIA $5.458 0.00238 1 $12.99 0.00242 1 $13.21 Seto (12) 2000 discounted
Minor bleed $3.901 0.01666 7 $64.99 0.04840 20 $188.81 Seto (12) 2000 discounted
Major bleed $30.188 0.01190 5 $359.24 0.01937 8 $584.74 Seto (12) 2000 discounted
Death $7.355 0.02143 9 $157.62 0.00968 4 $71.20 Seto (12) 2000 discounted
Total per patient
outcome cost
$863.42 Total per patient
outcome cost
$994.51
CVA  cardiovascular accident; TIA  transient ischemic attack.
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Cost Analysis of Cardioversion in AF April 7, 2004:1217–24ajor cost-related variables that are linked to the different
trategies include the cost of treatment, length of stay, and
ost of treating adverse events. In this study, the cost of the
EE procedure added to the treatment costs of the TEE-
uided strategy as might be expected. However, the cumu-
ative costs of treating adverse events were found to be
igher in the conventional group, driven by the higher
leeding rate for conventional patients with prolonged
nticoagulation (21).
In summary, over an eight-week period, the cost of a
EE-guided strategy showed no significant difference from
he conventional strategy. Using mean costs ($269) or using
ootstrap results ($386), the TEE-guided approach was
lightly more costly. Conversely, the difference in overall
osts between the two strategies amounted to 5% of the
otal hospital and physician costs, which might not be
onsidered economically significant.
Our study evaluated eight-week hospital and physician
ean costs that were derived from hospital and physician
otal charges using hospital cost/charges (11,15). This
activity-based” method uses the more traditional “top-
own” accounting methodology including charge-to-cost
onversion (22). The benefit of this approach is that it may
e more adaptable to other U.S. hospital settings. However,
t does not detail individual costs as with a “microcosting”
pproach. As such, it can be more difficult to identify in
etail the major contributors to overall cost. We used
egression analysis to estimate the effects of different param-
ters on cost including adverse events. However, we felt it
ise to introduce a completely separate “analytic” costing
pproach to validate the results of our “top-down” costing
trategy. The analytic model did not incorporate every
ossible resource used, but it did detail a number of costs
elated to the treatment of patients in the TEE-guided and
onventionally treated groups of the ACUTE study in a
icrocosting fashion. The actual incidence of resource
sage was based on the ACUTE trial. However, the costs
ere derived from a number of published sources. The
nalytic approach allowed testing in the form of sensitivity
nalysis, a standard approach in economic analysis to inves-
igate the potential cost differences (i.e., cost “drivers”) in
arying healthcare settings. The analytic model showed
verall lower costs than those found in the ACUTE
conomic substudy. However, its message was the same,
eflecting and supporting our primary cost analysis using
ospital and physician charge data. There were little overall
ost differences ($80) between the treatment strategies.
Table 6. ACUTE Trial Analytic Model Summ
TEE treatment per patient $2,639.67
TEE outcomes per patient $863.42
Total TEE-guided costs per patient $3,503.09
Difference in total costs
Percent difference
TEE transesophageal echocardiography.ensitivity analysis. In addition, increasing the incidence
nd cost of major bleeding, as well as the cost of TEE, has
he most extensive impact on cost differences between the
EE-guided and conventionally treated groups. However,
he sensitivity analysis had little overall impact on the
conomic consequences of using the TEE-guided strategy
s opposed to conventional strategy.
ost-effectiveness model. Seto et al. (12) evaluated the
ost effectiveness of the two approaches in hospitalized
atients with recent onset AF, using a decision analytic
odel. Costs per quality-adjusted life year (QALY) were
ompared for three strategies: TEE-guided alone, TTE/
EE-guided, and conventional approaches. The authors
oncluded that the TEE-guided approach without TTE
ad a lower total cost and higher effectiveness ($2,774 per
.49 QALY) compared with the TTE/TEE-guided ap-
roach ($3,106 per 8.48 QALY) and the conventional
pproach ($3,070 per 8.48 QALY). Thus, the TEE-guided
pproach was considered to dominate over the other two
trategies. In this study, many assumptions based on a range
f published sources were used for event probabilities and
osts.
Our group developed a similar, albeit more basic, decision
ost-effectiveness model (see Appendix for method and
omprehensive results). This decision tree analysis used
vent probabilities and costs derived from the ACUTE trial.
he decision tree model showed that the TEE-guided
trategy was more costly by $185 when all treatment and
utcome data were factored ($7,090 vs. $6,905). This
ost-effectiveness model was developed for the eight-week
tudy period only, unlike the Seto et al. (12) model, which
ncluded long-term survival. In our model, the conventional
trategy dominated the TEE-guided strategy due to the
igher incidence of death in the TEE group (which was not
he case in Seto et al.’s model). However, the probability of
eath was not statistically different between the two strate-
ies, and, when during sensitivity analysis, death was elim-
nated from the model, the TEE-guided group showed an
ncremental cost-effectiveness ratio (ICER) of $15,455 per
ALY. An ICER of $50,000 per QALY is considered a
ost-effective approach for life saving interventions. Thus,
he TEE-guided strategy would be considered a cost-
ffective alternative to the conventional strategy (23). If
ong-term follow-up were factored, it is likely that the TEE
pproach would prove even more cost-effective.
The incidence of stroke, major and minor bleeding, and
eath were higher in the Seto et al. (12) model than those
ound in the ACUTE study. The Seto et al. (12) costs for
Conventional treatment per patient $2,429.01
Conventional outcomes per patient $994.51
Total conventional cost per patient $3,423.52
$79.57
2.27%ary
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han those found in our study. Costs of stroke and major
leeding were similar in both studies. These differences,
ombined with the fact that Seto et al. incorporated long-
erm follow-up, would explain why their model was more
ost-effective than the one generated by our group. Further
nvestigation would be required to generate the true long-
erm consequences of the different strategies for treating
atients with AF.
linical implications. Atrial fibrillation is a very costly
ublic health problem which imposes a large economic
urden on health care (24). The results of our economic
tudy show that a TEE-guided approach is only slightly
igure 2. Sensitivity of the effect of varying the incidence and the cost of
major bleeding event (A) on the difference in the treatment costs between
transesophageal echocardiography (TEE)-guided and conventionally
reated patient for the analytic model; effect of varying the cost of TEE on
he difference in treatment costs (B) (including adverse events) between a
EE-guided and conventionally treated patient for the analytic model.
he y axis shows the difference in cost of treating a TEE-guided patient
inus a conventionally treated patient in dollars. The x axis shows the cost
f the clinical event or TEE. Above the 0 baseline is more costly for TEE,
nd below the baseline is less costly for TEE. The star points to the actual
ifference in treatment costs.ore costly than the conventional approach, although sutcome costs tended to be higher for the conventional
trategy, resulting in no significant cost difference between
he two strategies. The cost of the TEE procedure itself
$277 using Medicare reimbursement) is a relatively small
ortion of the $6,400 total eight-week management cost for
atients undergoing cardioversion for AF. Therefore, this is
n economically feasible alternative to conventional therapy.
n the current era of rate control and prolonged anticoag-
lation (25), what then is the role of the TEE-guided
pproach to cardioversion? In clinical practice, the choice of
he approach should be individualized to each AF patient.
he TEE-guided approach is useful for the symptomatic
oung patient with new onset AF, for patients at high risk
or stroke and bleeding, and for hospitalized patients in
hom the TEE can help stratify patients by the detection of
AA thrombus, spontaneous echo contrast, and complex
theroma (26,27). In patients who are unlikely to have
pontaneous conversion, the TEE-guided approach should
e considered as well (28). Economic factors alone should
ot determine the choice of strategies to cardioversion.
CUTE II study. Recently, our group has proposed the
se of short-term low-molecular-weight heparin as a bridge
o therapeutic warfarin therapy and TEE-guided cardiover-
ion in the on-going ACUTE II study. This bridging
pproach has the potential to lower costs by treating patients
s outpatients instead of in-patients and to increase patient
onvenience and quality of life compared with the use of
ntravenous heparin (29). The TEE-guided approach with
ow molecular weight heparin (Enoxaparin) may be the
referred approach as shown recently in the Anticoagulation
n Cardioversion Using Enoxaparin (ACE) trial (30).
tudy limitations. There are several limitations of the
CUTE economic substudy. Only U.S. clinical centers
ere used for analysis, and they may represent different
linical costs than non-U.S. sites. The marked variability in
harges from hospital to hospital and among individual
atients provides a considerable challenge in healthcare cost
nalysis. A number of techniques were introduced to try to
anage these issues.
In addition, due to the sensitivity of publishing hospital
ost data, data collection for economic studies is often
ifficult. Cost data for 44% of our U.S. patient population
ere unable to be collected. The data for these patients were
mputed based on the data collected for the other patients
nrolled in U.S. hospitals. It was recognized that this
esulted in the use of cost estimates, and, thus, there was a
eed to validate our findings with an analytic model.
Finally, we used UB-92s to calculate costs. This may be
imited because it does not include patient self-reporting of
ffice visits, home health services, rehabilitation, and use of
edication. Therefore, our outpatient or follow-up costs
ay underestimate the true healthcare costs of these pa-
ients.
onclusions. In patients with AF 2 days’ duration un-
ergoing electrical cardioversion, the TEE-guided group
howed little difference in patient costs compared with the
c
t
l
p
b
f
R
C
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
A
F
1224 Klein et al. JACC Vol. 43, No. 7, 2004
Cost Analysis of Cardioversion in AF April 7, 2004:1217–24onventional group. The TEE strategy had higher initial
reatment costs but lower outcome-associated costs. Cumu-
ative costs were 24% higher in the conventional group,
rimarily due to bleeding and hospital costs associated with
leeding. The TEE-guided strategy is an economically
easible approach compared with the conventional strategy.
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